Costs keep women from taking drugs to prevent cancer’s return

(Reuters Health) - Poverty and higher out-of-pocket drug costs may be the main reason that some women don’t stick with hormone therapy designed to prevent breast cancer from coming back, a recent U.S. study suggests.

India says it is committed to global tobacco-control treaty

NEW DELHI (Reuters) - India reaffirmed on Tuesday its commitment to a World Health Organization (WHO) tobacco-control treaty, despite lobbying from its $11 billion industry that opposes some measures in the treaty that will be discussed at a conference next week.

Novartis's LEE011 gets FDA fast track in advanced breast cancer

ZURICH (Reuters) - The U.S. Food and Drug Administration has granted priority review status for Novartis drug LEE011 (ribociclib) as a first-line treatment of postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with letrozole, the Swiss drugmaker said on Tuesday.